TEMPEST THERAPEUTICS INC
TPSTNASDAQTrading Snapshot
- Day Range
- $0.81 – $0.82
- 52-Week Range
- $0.74 – $12.23
- Volume
- $2.81B
- Avg Volume
- $3.53B
- Shares Outstanding
- 16.0M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $297,336
- Last Q Revenue
- $80,326
- P/E Ratio
- —
- P/S Ratio
- 44.7x
- EPS (TTM)
- $-4.49
- Dividend Yield
- —
- Dilution (1yr)
- −85.1%
Why Investors Own TPST
- ✓High-growth profile — revenue up +4.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 43% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TEMPEST THERAPEUTICS INC
TPST
StockOtter · stockotter.spaceAbout TEMPEST THERAPEUTICS INC
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Tempest signs related-party R&D pact, reshapes leadership
What happened Tempest Therapeutics, Inc. (NASDAQ: TPST) said on September 22, 2026, that it signed a Master Services Agreement with Factor Bioscience Inc. The agreement covers research and development services under work
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immuni
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potential aggregate gross p
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer